

## Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

Table 2g. Annual reported cases\* of notifiable diseases, by region and reporting area, United States, U.S. Territories and Non-U.S. Residents, 2023

Reporting Area	Diphtheria	Ehrlichiosis and Anaplasmosis				Giardiasis	Gonorrhea†
		<i>Anaplasma phagocytophilum</i> infection†	<i>Ehrlichia chaffeensis</i> infection†	<i>Ehrlichia ewingii</i> infection	Undetermined ehrlichiosis/ anaplasmosis		
U.S. Residents, excluding U.S. Territories	2	7,279	1,907	26	89	16,178	601,262
New England	—	2,261	29	—	2	1,072	16,977
Connecticut	—	65	6	N	N	189	4,098
Maine	—	777	3	—	—	149	620
Massachusetts	—	741	12	—	2	582	9,786
New Hampshire	—	133	—	—	—	87	588
Rhode Island	—	84	6	—	—	65	1,665
Vermont	—	461	2	—	—	N	220
Middle Atlantic	1	3,504	358	5	9	3,472	74,994
New Jersey	—	195	106	3	—	483	10,134
New York (excluding New York City)	—	1,939	180	1	2	992	13,552
New York City	1	78	9	1	—	1,348	32,550
Pennsylvania	—	1,292	63	—	7	649	18,758
East North Central	—	782	181	4	22	1,669	77,344
Illinois	—	34	55	—	—	N	25,387
Indiana	—	2	60	2	—	192	9,881
Michigan	—	64	6	—	—	508	15,274
Ohio	—	12	13	—	1	453	19,795
Wisconsin	—	670	47	2	21	516	7,007
West North Central	—	541	569	13	33	1,246	33,979
Iowa	—	12	15	—	1	201	3,747
Kansas	—	4	55	5	—	138	4,234
Minnesota	—	508	7	1	14	444	7,717
Missouri	—	11	474	7	18	263	12,513
Nebraska	—	—	14	—	—	90	2,285
North Dakota	—	5	—	—	—	31	1,154
South Dakota	—	1	4	—	—	79	2,329
South Atlantic	1	135	357	—	13	2,786	150,262
Delaware	—	5	18	—	—	41	1,567
District of Columbia	—	—	—	—	1	102	5,794
Florida	—	43	41	—	—	1,311	46,726
Georgia	—	2	13	—	—	553	30,307
Maryland	—	29	55	—	—	224	12,802
North Carolina	—	8	112	—	2	N	26,353
South Carolina	1	—	—	—	7	164	11,950
Virginia	—	31	98	—	3	307	13,795
West Virginia	—	17	20	—	—	84	968
East South Central	—	8	243	1	6	429	38,324
Alabama	—	1	4	—	—	216	11,584
Kentucky	—	4	129	1	6	213	6,072
Mississippi	—	1	3	—	—	N	7,382
Tennessee	—	2	107	—	—	N	13,286
West South Central	—	8	167	3	—	421	79,822
Arkansas	—	1	127	3	—	164	5,932
Louisiana	—	2	4	—	—	257	13,192
Oklahoma	—	3	22	—	—	N	6,905

Table 2g. Annual reported cases\* of notifiable diseases, by region and reporting area, United States, U.S. Territories and Non-U.S. Residents, 2023

Reporting Area	Diphtheria	Ehrlichiosis and Anaplasmosis				Giardiasis	Gonorrhea†
		<i>Anaplasma phagocytophilum</i> infection†	<i>Ehrlichia chaffeensis</i> infection†	<i>Ehrlichia ewingii</i> infection	Undetermined ehrlichiosis/anaplasmosis		
Texas	—	2	14	—	—	N	53,793
Mountain	—	10	3	—	1	1,571	36,302
Arizona	—	8	—	—	1	160	14,172
Colorado	—	N	N	N	N	690	7,563
Idaho	—	N	N	N	N	135	777
Montana	—	—	1	—	—	94	767
Nevada	—	—	1	—	—	102	6,538
New Mexico	—	N	N	N	N	91	3,574
Utah	—	2	—	—	—	253	2,664
Wyoming	—	—	1	—	—	46	247
Pacific	—	30	—	—	3	3,512	93,258
Alaska	—	N	N	N	N	62	2,280
California	—	22	—	—	3	2,757	74,071
Hawaii	—	N	N	N	N	46	1,818
Oregon	—	5	—	—	—	397	4,960
Washington	—	3	—	—	—	250	10,129
U.S. Territories	—	—	—	—	—	24	1,536
American Samoa	—	N	N	N	N	—	40
Commonwealth of Northern Mariana Islands	—	—	—	—	—	—	38
Guam	—	N	N	N	N	—	188
Puerto Rico	—	N	N	N	N	18	1,187
U.S. Virgin Islands	—	—	—	—	—	6	83
Non-U.S. Residents	—	—	—	—	—	7	25
Total	2	7,279	1,907	26	89	16,209	602,823

—: No reported cases — The reporting jurisdiction did not submit any cases to CDC.

N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.

U: Unavailable — The data are unavailable.

\* Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see the [Guide to Interpreting Provisional and Finalized NNDSS Data](#).

† New Mexico designated *E. chaffeensis* and *A. phagocytophilum* as reportable diseases in 2023. However, this change is not reflected in the 2023 NNDSS annual tables, where these conditions are still marked with an 'N' and interpreted as 'Not Reportable.'

‡ Beginning in 2023, confirmed and probable cases of gonorrhea are published to align with the approved CSTE position statement 22-ID-03, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years.

#### Notes:

1. These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2023 annual tables were officially closed on November 7, 2024.

2. The list of national notifiable Infectious diseases and conditions for 2023 and their national surveillance case definitions are available by navigating to the [Surveillance Case Definitions | CDC](#) web page, selecting "2023" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2023 data are available at <https://www.cdc.gov/nndss/infectious-disease/notice-to-data-users.html>. See also [Guide to Interpreting Provisional and Finalized NNDSS Data](#).

3. Population estimates for incidence rates are July 1st, 2023 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2023, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2023" population estimates for years 2020–2023 were released February 2025 by the National Cancer Institute at <https://seer.cancer.gov/popdata/>. For more information, see <https://seer.cancer.gov/popdata/singleages.html>. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.

4. Annual tables for 2016 and later years are available on [CDC WONDER's NNDSS Annual Summary Data Query](#).

5. Annual summary reports from 1993–2015 are available as published in the [Morbidity and Mortality Weekly Report](#).

6. NNDSS annual tables since 1952 are available at [CDC Stacks](#). To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Resource Type Specific" section on the left-hand side and select "Annual Reports" (1952–2015) or "Annual Tables" (2016–present).

7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

Age restrictions in the numerator and denominator are applied for the following childhood conditions:

Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)

Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)  
*Haemophilus influenzae*, invasive disease <5 years (age restriction in numerator and denominator is <5 years)  
Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)  
Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)  
Infant botulism (age restriction in numerator and denominator is <1 year)  
Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)  
Perinatal hepatitis B infection (age restriction in numerator is ≤24 months; however, rates will not be calculated due to population estimates not being available for the specific sub-population required to align with the defined age restriction criteria)  
Perinatal hepatitis C infection (age restriction in numerator is ≤36 months; however, rates will not be calculated due to population estimates not being available for the specific sub-population required to align with the defined age restriction criteria).

Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2023 (National Center for Health Statistics [Nativity 2023](#), as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).

**Suggested Citation:**

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2023 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Office of Public Health Data, Surveillance, and Technology, 2025. Available at: <https://www.cdc.gov/nndss/infectious-disease/>.

**Acknowledgment:**

CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.

National Notifiable Diseases Surveillance System